Eisai and Biogen's Alzheimer's success leaves many questions still unanswered
When the celebrations over the companies’ recent Alzheimer’s breakthrough were over, some were left asking questions – like what about the treatment’s efficacy and side effects, and how much will it cost?
By Robert Langreth, bloomberg
Shares of Eisai Co. and partner Biogen Inc. have soared since reporting that their drug lecanemab slowed Alzheimer’s, the first to unambiguously impede the progression of the disease in a final-stage trial. But many questions linger.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.